Lower respiratory tract microbiome dysbiosis impairs clinical responses to immune checkpoint blockade in advanced non-small-cell lung cancer
Yong Zhang , Xiang-Xiang Chen , Ruo Chen , Ling Li , Qing Ju , Dan Qiu , Yuan Wang , Peng-Yu Jing , Ning Chang , Min Wang , Jian Zhang , Zhi-Nan Chen , Ke Wang
Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (1) : e70170
Lower respiratory tract microbiome dysbiosis impairs clinical responses to immune checkpoint blockade in advanced non-small-cell lung cancer
•Alterations of the lower respiratory tract microbiome indicate different clinical responses to ICB within advanced NSCLC. | |
•Reduced microbial diversity of lower respiratory tracts impairs anti-tumoral performances. | |
•Microbe-derived metabolites perform as a dominant regulator to remodify the microecological environment in lower respiratory tracts. | |
•Multi-omics sequencings of the lower respiratory tract possess the potential to predict the long-term clinical responses to ICB among advanced NSCLC. |
advanced non-small-cell lung cancer / clinical outcomes / immune checkpoint blockade therapy / lower respiratory tract microbiome / multi-omics analysis
2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
/
| 〈 |
|
〉 |
PDF
